KCAS Bio will be exhibiting at AAPS PharmSci 360 on October 25th – 28th in New Orleans, LA. Visit us at Booth #1037.
AAPS PharmSci 360 brings together pharmaceutical scientists and industry leaders to explore advances across the drug development lifecycle, from discovery and preclinical research through clinical development and regulatory science. The conference provides a collaborative environment for sharing scientific insights, addressing industry challenges, and advancing innovative therapies.
KCAS Bio Presentations at PharmSci
October 26th | 11:00am | Stage 4 | Join Dawn Dufield, Ph.D. for “Fit-for-Purpose Biomarker Validation and LC-MS/MS Case Studies on SCIEX Platforms.”
Biomarker assays require validation strategies aligned with their intended context of use. This presentation reviews fit-for-purpose biomarker validation from a CRO perspective and demonstrates how analytical requirements evolve from exploratory research through decision-enabling applications. Case studies using hybrid and traditional LC-MS/MS workflows on SCIEX 6500+, 7500+, and ZenoTOF 8600 platforms will illustrate platform selection, parallelism, surrogate matrix strategies, and validation approaches for protein and small-molecule biomarkers.
October 26th | 3:30pm – 3:45pm | Join Dawn Dufield, Ph.D. for a rapid fire talk on “Application of PPT and SPE for Oligonucleotides in Ring Trial.”
October 27th | 3:30pm | Stage 2 | Join Lindsay Rutherford, Ph.D. for “The Evolving Biomarker Landscape: Emerging Technologies, and Translational Case Studies.”
Biomarker analysis continues to evolve as increasingly sensitive and multiplexed technologies expand opportunities across drug development. This presentation will examine the biomarker landscape, emphasizing how context of use guides platform selection, assay development, and fit-for-purpose validation. Emerging technologies, including ultrasensitive and high-plex platforms, will be compared with established approaches. Real-world case studies will highlight challenges involving critical reagents, sample collection and processing, matrix variability, assay robustness, and selection of appropriate analytical technologies.
KCAS Bio Poster at PharmSci
October 28th | 9:30am – 10:30am | Fluorescence Detection by HPLC-FLD of Antibodies and Other Complex Proteins at Low Concentrations Utilizing Intrinsic Fluorescence for Reliable Protein Characterization by Sydney Spears
Pharmaceutical Sciences at KCAS Bio
KCAS Bio has expertise in pharmacokinetic, pharmacodynamic, biomarker, and immunogenicity assessments through ligand binding assays (LBA), LC-MS/MS, hybrid LC-MS/MS, molecular assays, and biomarker testing. We partner with large pharmaceutical and biotechnology companies to develop fit-for-purpose programs that generate high-quality data and support informed decision-making throughout drug development.
Connect With Us at AAPS PharmSci 360
Visit us at Booth #1037 to discuss your program and learn how our bioanalytical expertise can help move your therapy forward. Fill out the form below to reach out to a scientist.